Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Sucampo Kicks Off Study for Peripheral Arterial Disease Treatment
RxTrials Institute Drug Pipeline Alert
Dec. 24, 2008 | Vol. 6 No. 52
Sucampo Kicks Off Study for Peripheral Arterial Disease Treatment
Sucampo Pharma has started dosing patients in a Phase I study of its proprietary prostone, SPL-017, as a potential treatment for peripheral arterial disease.
Peripheral arterial disease is the narrowing or blockage of arteries that results in poor blood flow to the arms and legs.
The randomized, double-blind, placebo-controlled, single-center, single-ascending dose study will evaluate the safety and pharmacokinetic profile of the drug. A total of 74 healthy adult male subjects will be enrolled in eight dose groups, receiving intravenous doses of the drug ranging from 3 mcg to 360 mcg, Sucampo said.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.